Knockouts model the 100 best-selling drugs - Will they model the next 100?

Nature Reviews Drug Discovery

Volumn 2, Issue 1, 2003, Pages 38-51

  Zambrowicz, Brian P ^a   Sands, Arthur T ^a  

^a LEXICON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALENDRONIC ACID; BEXAROTENE; BOSENTAN; CELECOXIB; CLOPIDOGREL; DROTRECOGIN; EPTIFIBATIDE; ETANERCEPT; FAMOTIDINE; GEMTUZUMAB OZOGAMICIN; IMATINIB; INFLIXIMAB; LANSOPRAZOLE; LOSARTAN POTASSIUM; METFORMIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NESIRITIDE; OMEPRAZOLE; PANTOPRAZOLE; RANITIDINE; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SILDENAFIL; TETRAHYDROLIPSTATIN; TIROFIBAN; TRASTUZUMAB; TROGLITAZONE; UNINDEXED DRUG; ZAFIRLUKAST; DRUG RECEPTOR;

ARTHRITIS; CHRONIC MYELOID LEUKEMIA; CORRELATION ANALYSIS; DISEASE MODEL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TARGETING; ERECTILE DYSFUNCTION; GASTROESOPHAGEAL REFLUX; GENE SEQUENCE; GENETIC IDENTIFICATION; GENETIC SCREENING; HEMATOLOGIC DISEASE; HUMAN; KNOCKOUT MOUSE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; ANIMAL; GENE TARGETING; GENETICS; METHODOLOGY; MOUSE; MOUSE MUTANT; PHARMACOLOGY;

ANIMALS; GENE TARGETING; HUMANS; MICE; MICE, KNOCKOUT; PHARMACOLOGY; RECEPTORS, DRUG;

EID: 0037267313     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd987     Document Type: Review

References (115)

1. Drews, J. Biotechnology's metamorphosis into a drug discovery industry. Nature Biotechnol. 16, (Suppl) 22-24 (1998).
2. Hopkins, A. L. & Groom, C. R. The druggable genome. Nature Rev. Drug Discov. 1, 727-30 (2002).
3. PharmaLive. com. The Med Ad News 200- the world's bestselling medicines, May 2002. Engel Publishing Partners, Reprinted with permission from Med Ad News, (May 2002) (PharmaLive.com, West Trenton, NJ, 2002).
4. FDA. FDA. (Center for Drug Evaluation and Research, Rockville, MD, CDER Report to the Nation, 1997-2001).
5. Vinson, M. C., Davis, W. M. & Waters, I. W. (Drug Topics, Montvale, NJ, New Drug Approvals of 1995-1997).
6. Kaitin, K. I. & Manocchia, M. The new drug approvals of 1993, 1994, and 1995: trends in drug development. Am. J. Ther. 4, 46-54 (1997).
7. Scappini, B. et al. In vitro effects of STI571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer 94, 2653-2662 (2002).
8. Walke, D. W. et al. In vivo drug target discovery: identifying the best targets from the genome. Curr. Opin. Biotechnol. 12, 626-631 (2001).
9. Abuin, A., Holt, K. H., Platt, K. A., Sands, A. T. & Zambrowicz, B. P. Full-speed mammalian genetics: in vivo target validation in the drug discovery process. Trends Biotechnol. 20, 36-42 (2002).
10. BusinessCommunicationsCompany. (Business Communications Company, Inc., Norwalk, CT, 2002).
11. Spicer, Z. et al. Stomachs of mice lacking the gastric H,K-ATPase α-subunit have achlorhydria, abnormal parietal cells, and ciliated metaplasia. J. Biol. Chem. 275, 21555-21565 (2000).
12. Scarff, K. L., Judd, L. M., Toh, B. H., Gleeson, P. A. & Van Driel, I. R. Gastric H(+),K(+)-adenosine triphosphatase β subunit is required for normal function, development, and membrane structure of mouse parietal cells. Gastroenterology 117, 605-668 (1999).
13. 2 receptor-deficient mice. J. Clin. Invest. 105, 1741-1749 (2000).
14. Wu, C. S, Lim, S. K., D'Agati, V. & Costantini, F. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 83, 59-67 (1996).
15. Lieschke, G. J. et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 84, 1737-1746 (1994).
16. Banu, Y. & Watanabe, T. Augmentation of antigen receptor-mediated responses by histamine H1 receptor signaling. J. Exp. Med. 189, 673-682 (1999).
17. 2 receptors. Nature 413, 420-425 (2001).
18. Yanai, K. et al. Behavioural characterization and amounts of brain monoamines and their metabolites in mice lacking histamine H. receptors. Neuroscience 87, 479-487 (1998).
19. 1 receptors. Proc. Natl Acad. Sci. USA 93, 13316-13320 (1996).
20. 1 receptors in mice: behavioral and neurochemical characterization. Life Sci. 62, 1607-1610 (1998).
21. Tilley, S. L., Coffman, T. M. & Koller, B. H. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J. Clin. Invest. 108, 15-23 (2001).
22. Morteau, O. Prostaglandins and inflammation: the cyclooxygenase controversy. Arch. Immunol. Ther. Exp. 48, 473-480 (2000).
23. Austin, S. C. & Funk, C. D. Insight into prostaglandin, leukotriene, and other eicosanoid functions using mice with targeted gene disruptions. Prostaglandins Other Lipid Mediat. 58, 231-252 (1999).
24. Lanqenbach, R., Loftin, C., Lee, C. & Tiano, H. Cyclooxygenase knockout mice: models for elucidating isoform-specific functions. Biochem. Pharmacol. 58, 1237-1246 (1999).
25. Williams, C. S., Mann, M. & DuBois, R. N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18, 7908-7916 (1999).
26. Langenbach, R. et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83, 483-492 (1995).
27. Langenbach, R., Loftin. C. D., Lee, C. & Tiano, H. Cyclooxygenase-deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis. Ann. NY Acad. Sci. 889, 52-61 (1999).
28. Reddy, S. T., Tiano, H. F., Lanqenbach, R., Morham, S. G. & Herschman, H. R. Genetic evidence for distinct roles of COX-1 and COX-2 in the immediate and delayed phases of prostaglandin synthesis in mast cells. Biochem. Biophys. Res. Commun. 265, 205-210 (1999).
29. Morteau, O. et al. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J. Clin. Invest. 105, 469-478 (2000).
30. Ballou, L. R., Botting, R. M., Goorha, S., Zhang, J. & Vane, J. R. Nociception in cyclooxygenase isozyme-deficient mice. Proc. Natl Acad. Sci. USA 97, 10272-10276 (2000).
31. Chulada, P. C. et al. Cycloxygenase-1 and-2 deficiency decrease spontaneous intestinal adenomas in the Min mouse. Proc. Am. Assoc. Cancer Res. 39, 195 (1998).
32. Tiano, H. F. et al. Effects of cyclooxygenase deficiency on inflammation and papilloma formation in mouse skin. Proc. Am. Assoc. Cancer Res. 38, 257 (1998).
33. Morham, S. G. et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83, 473-482 (1995).
34. Li, S. et al. The febrile response to lipopolysaccharide is blocked in cyclooxygenase- 2(-/-), but not in cyclooxygenase-1(-/-) mice. Brain Res. 825, 86-94 (1999).
35. Myers, L. K. et al. The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. Arthritis Rheum. 43, 2687-2693 (2000).
36. Oshima, M. et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87, 803-809 (1996).
37. Irvin, C. G., Tu, Y. P., Sheller, J. R. & Funk, C. D. 5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice. Am. J. Physiol. 272, L1053-1058 (1997).
38. Peters-Golden, M. et al. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am. J. Respir. Crit. Care Med. 165, 229-235 (2002).
39. Chen, X. S., Sheller, J. R., Johnson, E. N. & Funk, C. D. Role of leukotrienes revealed by targeted disruption of the 5- lipoxygenase gene. Nature 372, 179-182 (1994).
40. Maekawa, A., Austen, K. F. & Kanaoka, Y. Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses. J. Biol. Chem. 277, 20820-20824 (2002).
41. Pasparakis, M., Alexopoulou, L., Episkopou, V. & Kollias, G. Immune and inflammatory responses in TNF α-deficient mice: a critical requirement for TNF α in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med. 184, 1397-1411 (1996).
42. Marino, M. W. et al. Characterization of tumor necrosis factor-deficient mice. Proc. Natl Acad. Sci. USA 94, 8093-8098 (1997).
43. Gu, J. J. et al. Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II gene. J. Clin. Invest. 106, 599-606 (2000).
44. Schmid, W., Cole, T. J., Blendy, J. A. & Schutz, G. Molecular genetic analysis of glucocorticoid signalling in development. J. Steroid Biochem. 53, 33-35 (1995).
45. Reichardt, H. M., Tronche, F., Bauer, A. & Schutz, G. Molecular genetic analysis of glucocorticoid signaling using the Cre/IoxP system. Biol. Chem, 381, 961-964 (2000).
46. Bueno, O. F., Brandt, E. B., Rothenberg, M. E. & Molkentln, J. D. Defective T cell development and function in calcineurin Aβ-deficient mice. Proc. Natl Acad. Sci. USA 99, 9398-9403 (2002).
47. Malleret, G., Hen, R., Guillou, J. L., Segu, L. & Buhot, M. C. 5-HT1B receptor knock-out mice exhibit increased exploratory activity and enhanced spatial memory performance in the Morris water maze. J. Neurosci. 19, 6157-6168 (1999).
48. Grailhe, R. et al. Increased exploratory activity and altered response to LSD In mice lacking the 5-HT(5A) receptor. Neuron 22, 581-591 (1999).
49. Tecott, L. H., Logue, S. F., Wehner, J. M. & Kauer, J. A. Perturbed dentate gyrus function in serotonin 5-HT2C receptor mutant mice. Proc. Natl Acad. Sci. USA 95, 15026-15031 (1998).
50. Ramboz, S. et al. Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Prod. Natl Acad. Sci. USA 95, 14476-14481 (1998).
51. Parks, C. L., Robinson, P. S., Sibille, E., Shenk, T. & Toth, M. Increased anxiety of mice lacking the serotonin1A receptor. Pros. Natl Acad. Sci. USA 95, 10734-10739 (1998).
52. 1A receptor mutant mice. Proc. Natl Acad. Sci. USA 95, 15049-15054 (1998).
53. 1B receptor knock out-behavioral consequences. Behav. Brain Res. 73, 305-312 (1996).
54. Mayorga, A. J. et al. Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice. J. Pharmacol. Exp. Ther. 298, 1101-1107 (2001).
55. 4 receptor-knock-out mice exhibit reduced exploration of novel stimuli. J. Neurospi. 19, 9550-9556 (1999).
56. 2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J. Neurosc.i 18, 3470-3479 (1998).
57. 3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron 19, 837-848 (1997).
58. 1A dopamine receptors. Neuroscience 86, 135-146 (1998).
59. 1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell 79, 729-742 (1994).
60. 4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. Cell 90, 991-1001 (1997).
61. Giros, B., Jaber, M., Jones, S. R., Wightman, R. M. & Caron, M. G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606-612 (1996).
62. Xu, F. et al. Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nature Neurosci. 3, 465-471 (2000).
63. Homanics, G. E. et al. Mice devoid of γ-aminobutyrate type A receptor β3 subunit have epilepsy, cleft palate, and hypersensitive behavior. Proc. Natl Acad. Sci. USA 94, 4143-4148 (1997).
64. Sora, I. et al. Opiate receptor knockout mice define μ receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc. Natl Acad. Sci. USA 94, 1544-1549 (1997).
65. Schomberg, D. W. et al. Targeted disruption of the estrogen receptor-α gene in female mice: characterization of ovarian responses and phenotype in the adult. Endocrinology 140, 2733-2744 (1999 ).
66. Dupont, S. et al. Effect of single and compound knockouts of estrogen receptors α (ERα) and β (ERβ) on mouse reproductive phenotypes. Development 127, 4277-4291 (2000).
67. Vidal, O. et al. Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice. Proc. Natl Acad. Sci. USA 97, 5474-5479. (2000).
68. Krege, J. H. et al. Generation and reproductive phenotypes of mice lacking estrogen receptor β. Proc. Natl Acad. Sci. USA 95, 15677-15682 (1998).
69. Dunford, J. E. et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296, 235-242 (2001).
70. Thompson, K., Dunford, J. E., Ebetino, F. H. & Rogers, M. J. Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase. Biochem. Biophys. Res. Commun. 290, 869-873 (2002).
71. Grove, J. E., Brown, R. J. & Watts, D. J. The intracellular target for the antiresorptive aminobisphosphonate drugs in Dictyostelium discoideum is the enzyme farnesyl diphosphate synthase. J. Bone. Miner. Res. 15, 971-981 (2000).
72. Bergstrom, J. D., Bostedor, R. G., Masarachia, P. J., Reszka, A. A. & Rodan, G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch. Biochem. Biophys. 373, 231-241 (2000).
73. Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167-1174 (2001).
74. Abu-Elheiga, L., Matzuk, M. M., Abo-Hasema, K. A. H. & Wakil, S. J. Continuous fatty acid oxidation and reduced fat storage in mice lacking Acetyl-CoA carboxylase 2. Science 291, 2613-2616 (2001).
75. Leroux, L. et al. Compensatory responses in mice carrying a null mutation for Ins1 or Ins2. Diabetes 50, (Suppl 1) S150-153 (2001).
76. Joshi, R. L. et al. Targeted disruption of the insulin receptor gene in the mouse results in neonatal lethality. EMBO J. 15, 1542-1547 (1996).
77. Accili, D. et al. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nature Genet 12, 106-109 (1996).
78. Wang, J. et al. A mutation in the insulin 2 gene induces diabetes with severe pancreatic β-cell dysfunction in the Mody mouse. J. Clin. Invest. 103, 27-37 (1999).
79. Oyadomari, S. et al. Targeted disruption of the Chop gene delays endoplasmic reticulum stress-mediated diabetes. J. Clin. Invest. 109, 525-532 (2002).
80. Miles, P. D., Barak, Y., He, W., Evans, R. M. & Olefsky, J. M. Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency. J. Clin. Invest. 105, 287-292 (2000).
81. Lowe, M. E., Kaplan, M. H., Jackson-Grusby, L., D'Agostino, D. & Grusby, M. J. Decreased neonatal dietary fat absorption and T cell cytotoxicity in pancreatic lipase-related protein 2-deficient mice. J. Biol. Chem. 273, 31215-31221 (1998).
82. Weng, W. et al. Intestinal absorption of dietary cholesteryl ester is decreased but retinyl ester absorption is normal in carboxyl ester lipase knockout mice. Biochemistry 38, 4143-4149 (1999).
83. Ito, M. et al. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc. Natl Acad. Sci. USA 92, 3521-3525 (1995).
84. Sugaya, T. et al. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J. Biol. Chem. 270, 1871-18722 (1995).
85. Esther, C. R., Jr. et al. Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab. Invest. 74, 953-65 (1996).
86. Krege, J. H. et al. Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 375, 146-148 (1995).
87. Foster, C. J. et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J. Clin. Invest. 107, 1591-1598 (2001).
88. Dewerchin, M. et al. Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice. Thromb. Haemost. 83, 185-190 (2000).
89. 2-adrenergic receptors. Mol. Pharmacol. 60, 955-962 (2001).
90. Naga Prasad, S. V., Nienaber, J. & Rockman, H. A. β-adrenergic axis and heart disease. Trends Genet. 17, S44-49 (2001 ).
91. Eckhart, A. D. & Koch, W. J. Transgenic studies of cardiac adrenergic receptor regulation. J. Pharmacol. Exp. Ther. 299, 1-5 (2001).
92. 4-adrenoceptor pharmacology. Naunyn. Schmiedebergs Arch. Pharmacol. 363, 87-93 (2001).
93. 2-adrenergic receptors. J. Biol. Chem. 274, 16701-8. (1999).
94. 2 adrenergic receptor gene. J. Biol. Chem. 274, 16694-700 (1999).
95. Rohrer, D. K. Physiological consequences of β-adrenergic receptor disruption. J. Mol. Med. 76, 764-772 (1998).
96. 3-adrenergic receptors. Endocr. J. 45 (Suppl) S9-13 (1998).
97. 3-adrenoceptor knockout mice: evidence for a new β-adrenergic receptor in brown adipose tissue. Br. J. Pharmacol. 124, 1684-1688 (1998).
98. 1-adrenergic receptor knockout mouse. Am. J. Physiol. 274, H1184-1193 (1998).
99. 3-adrenoceptor knockout mice. Mol. Pharmacol. 53, 670-675 (1998).
100. 2 adrenoceptors. Adv. Pharmacol. 42, 499-501 (1998).
101. 1-adrenergic receptor gene: developmental and cardiovascular effects. Proc. Natl Acad. Sci. USA 93, 7375-7380 (1996).
102. 3 subtype. Proc. Natl Acad Sci. USA 97, 9579-9584 (2000).
103. Li, E., Sucov, H. M., Lee, K. F., Evans, R. M. & Jaenisch, R. Normal development and growth of mice carrying a targeted disruption of the α 1 retinoic acid receptor gene. Proc. Natl Acad. Sci. USA 90, 1590-1594 (1993).
104. Luo, J., Pasceri, P., Conlon, R. A., Rossant, J. & Giguere, V. Mice lacking all Isoforms of retinoic acid receptor β develop normally and are susceptible to the teratogenic effects of retinoic acid. Mech. Dev 53, 61-71 (1995).
105. Lohnes, D. et al. Function of retinoic acid receptor γ in the mouse. Cell 73, 643-658 (1993).
106. Kwan, K. Y. & Wang, J. C. Mice lacking DNA topoisomerase IIIβ develop to maturity but show a reduced mean lifespan. Proc. Natl Acad. Sci. USA 98, 5717-5721 (2001).
107. Rao, C. V. & Lei, Z. M. Consequences of targeted inactivation of LH receptors. Mol. Cell. Endocrinol. 187, 57-67 (2002).
108. O'Keefe, T. L., Williams, G. T., Davies, S. L. & Neuberger, M. S. Mice carrying a CD20 gene disruption. Immunogenetics 48, 125-132 (1998).
109. Mural, R. J. et al. A comparison of whole-genome shotgun-derived mouse chromosome 16 and the human genome. Science 296, 1661-1671 (2002).
110. Saftig, P. et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl Acad. Sci. USA 95, 13453-13458 (1998).
111. Huszar, D. et al. Targeted disruption at the melanocortin-4 receptor results in obesity in mice. Cell 88, 131-141 (1997).
112. Chen, A. S. et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nature Genet. 26, 97-102 (2000).
113. Chen, Y. et al. Targeted disruption of the melanin-concentrating hormone receptor-1 results in hyperphagia and resistance to diet-induced obesity. Endocrinology 143, 2469-2477 (2002).
114. Marsh, D. J. et al. Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc. Natl Acad. Sci. USA 99, 3240-3245 (2002).
115. Ntambi, J. M. et al. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc. Natl Acad. Sci. USA 99, 11482-11486 (2002).